Coherus BioSciences, Inc.
http://www.coherus.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coherus BioSciences, Inc.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.
Clasp Launches With $150m To Develop Personalized T-Cell Engagers
Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Coherus: Udenyca Trajectory ‘Unknown’ But ‘Compelling’ With On-Body Launch
Coherus BioSciences has spoken in detail about its full suite of Udenyca pegfilgrastim biosimilar products and how it plans to return to growth and positive cash flow moving forward – although it cannot, for now, provide an estimate for 2024 revenues.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice